95%Confidence
0Views
FDASource
2026-03-06Date
Summary
Fresenius Kabi's vancomycin sterility issues complete a pattern of compounding facility failures, suggesting systemic quality control breakdowns. This could impact hospital antibiotic supplies and trigger broader regulatory action against the compounding operation.
Actionable: Immediately audit all Fresenius Kabi compounded products and establish alternative vancomycin sources.
AI Confidence: 95%
Data Points
firmFresenius Kabi Compounding, LLC
classificationClass II
statusOngoing
distributionUS Nationwide.
productvancomycin HCl, 1.5 grams, 1.5 grams added to 500 mL, 0.9% Sodium Chloride Injection, USP, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now